Protagenic Therapeutics (PTIX) said Wednesday that warrant exchanges and exercises in the past four business days yielded $3.1 million in cash.
The proceeds will be used to fund working capital and advance Protagenic's peptide-based drug candidates for stress and central-nervous-system disorders, according to a statement.
Meanwhile, the company said it executed a business combination with Phytanix Bio, integrating six programs under one company.
Price: 6.91, Change: +0.03, Percent Change: +0.39
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。